Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan’s JSR Corporation, is pleased to announce the extension of its partnership with NEXT Oncology, one of the world’s largest Phase I clinical trial networks in oncology. This strategic partnership will continue to combine Crown Bioscience’s extensive experience in developing clinically relevant cancer organoid and patient-derived xenograft (PDX) models with NEXT Oncology’s global clinical network and Phase I clinical trial expertise.
Through this expanded agreement, Crown Bioscience reaffirms its exclusive rights to provide services based on patient samples derived from NEXT Oncology’s industry-leading global clinical trial network. This collaboration underscores Crown Bioscience’s commitment to providing the most clinically relevant PDX and organoid models and solutions for translational cancer research.
Also Read: PCI Pharma Services Completes Acquisition of Ajinomoto Althea as Part of $1 Billion Investment Strategy Strengthening U.S. Pharmaceutical Manufacturing
“We are very pleased to continue our exclusive partnership with NEXT Oncology,” said John Gu, CEO of Crown Bioscience. “NEXT Oncology is recognized worldwide for its pioneering work in Phase I clinical trials in oncology. By extending this partnership, we can expand our portfolio and strengthen our position as a leading provider of translational oncology platforms and integrated solutions. Our combined expertise and global reach will ensure our biopharmaceutical partners rapid and scalable access to groundbreaking cancer models.”
“NEXT Oncology is pleased to continue our strong partnership with Crown Bioscience,” said Dr. Anthony Tolcher, CEO of NEXT Oncology. “Together, we will continue to develop new and highly relevant patient models that Crown’s biopharmaceutical partners can use to advance their translational oncology programs. Our joint efforts continue to support the mission of both companies to bring the best possible medicines to cancer patients.”
SOURCE: Businesswire